	US 12,116,592 B2
	Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (VSELs)
Mariusz Z. Ratajczak, Louisville, KY (US); Janina Ratajczak, Louisville, KY (US); Magdalena Kucia, Louisville, KY (US); and Donald Miller, Louisville, KY (US)
Assigned to University of Louisville Research Foundation, Inc., Louisville, KY (US)
Filed by University of Louisville Research Foundation, Inc., Louisville, KY (US)
Filed on Jul. 26, 2021, as Appl. No. 17/385,560.
Application 17/385,560 is a division of application No. 16/081,665, granted, now 11,072,777, previously published as PCT/US2017/020696, filed on Mar. 3, 2017.
Claims priority of provisional application 62/303,888, filed on Mar. 4, 2016.
Prior Publication US 2022/0056404 A1, Feb. 24, 2022
Int. Cl. A61K 35/28 (2015.01); A61K 31/19 (2006.01); A61K 38/09 (2006.01); A61P 43/00 (2006.01); C12N 5/0735 (2010.01); C12N 5/0775 (2010.01); C12N 15/113 (2010.01)

CPC C12N 5/0606 (2013.01) [A61K 31/19 (2013.01); A61K 35/28 (2013.01); A61K 38/09 (2013.01); A61P 43/00 (2018.01); C12N 5/0665 (2013.01); C12N 15/113 (2013.01); C12N 2500/38 (2013.01); C12N 2501/15 (2013.01); C12N 2501/31 (2013.01)]

3 Claims

1. A feeder cell-free cell culture comprising a plurality of VSELs, one or more ex vivo expanded VSELs, and a culture medium, wherein the culture medium comprises a bovine serum or a serum replacement, a histone deacetylase (HDAC) inhibitor selected from the group consisting of valproic acid (VPA), nicotinic acid (NA), and nicotinamide (NAM), luteinizing hormone (LH), follicle-stimulating hormone (FSH), and optionally transforming growth factor beta (TGFβ), which together are present in an effective amount to overcome quiescence of the VSELs, resulting in expansion of the VSELs.